Theravance Biopharma, Inc.TBPHNASDAQ
LOADING
|||
Revenue Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year revenue growth rate
Latest
-23.69%
↓ 187% below average
Average (39q)
27.13%
Historical baseline
Range
High:389.88%
Low:-70.28%
CAGR
-2.5%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | -23.69% |
| Q2 2025 | 70.23% |
| Q1 2025 | -17.95% |
| Q4 2024 | 11.18% |
| Q3 2024 | 18.32% |
| Q2 2024 | -1.70% |
| Q1 2024 | -17.43% |
| Q4 2023 | 11.93% |
| Q3 2023 | 14.14% |
| Q2 2023 | 31.99% |
| Q1 2023 | -28.89% |
| Q4 2022 | 17.65% |
| Q3 2022 | 12.68% |
| Q2 2022 | -16.26% |
| Q1 2022 | -11.71% |
| Q4 2021 | 13.28% |
| Q3 2021 | 2.17% |
| Q2 2021 | -9.42% |
| Q1 2021 | -23.88% |
| Q4 2020 | 2.59% |
| Q3 2020 | 21.65% |
| Q2 2020 | -24.44% |
| Q1 2020 | -32.67% |
| Q4 2019 | 137.38% |
| Q3 2019 | -52.48% |
| Q2 2019 | 389.88% |
| Q1 2019 | -66.08% |
| Q4 2018 | 22.58% |
| Q3 2018 | -45.31% |
| Q2 2018 | 182.20% |
| Q1 2018 | 84.25% |
| Q4 2017 | 5.61% |
| Q3 2017 | 21.83% |
| Q2 2017 | 13.67% |
| Q1 2017 | -45.77% |
| Q4 2016 | -70.16% |
| Q3 2016 | 248.66% |
| Q2 2016 | -70.28% |
| Q1 2016 | 372.90% |
| Q4 2015 | -63.61% |